We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Senesco Technologies reported the results of a mouse cancer study conducted at Ontario's University of Waterloo in which Factor 5A technology was used to treat mice with a type of melanoma that has an affinity for lung tissue which results in metastatic lung tumors.
CV Therapeutics has initiated a clinical program for CVT-6883, a selective, potent and orally available A2B-adenosine receptor antagonist intended to treat asthma with a daily dosage.
Medicure, a cardiovascular drug discovery and development company, announced that the 16 week treatment period is complete for all patients in a Phase II matched study, which is evaluating the effects of Medicure's MC-4232 in patients with coexisting Type 2 diabetes and hypertension.
OSI Pharmaceuticals and Genentech announced that The New England Journal of Medicine published results from the pivotal Phase III study showing Tarceva improved survival in patients with advanced non-small cell lung cancer (NSCLC).
Join FDAnews Tuesday, July 19, for a 90-minute audioconference on "Change
Control: Current Best Practices for FDA-Compliant Systems." Learn about
the FDA's latest change control requirements for processes, facilities, utilities,
equipment, computers, raw materials and documents from compliance expert, Barbara
Immel. On July 26, join FDAnews for "Equipment Qualification
and Process Validation Made Easy: Streamline Your System While Staying in Compliance."
Learn from Brian D. Callahan on how to increase consistency and reduce
time and resources when writing and performing qualifications. Also discover
how to break down your system into testable and manageable pieces to ensure
your quality system is up to current standards.
Biosite announced that it has signed an exclusive licensing agreement with Cincinnati
Children's Hospital Medical Center and Columbia University for the use of neutrophil
gelatinase-associated lipocalin (NGAL), a biomarker that may assist clinicians
to quickly and accurately identify acute renal failure within hours rather than
days, in diagnostic, monitoring and prognostic applications.
Hemosol announced that it has chosen Immune Globulin Intravenous 10 percent
(IGIV) as the first protein product that the company will advance through the
clinical development and regulatory process in order to seek approval to commence
commercial production.
Takeda Pharmaceuticals is the latest drug manufacturer to launch an online clinical
trials registry. The Japanese firm, which has U.S. headquarters in Lincolnshire,
Ill., said earlier this week it would begin disclosing late phase clinical data
on both its Japanese and North American websites.
Amarillo Biosciences announced it has resolved all clinical and safety issues
with the FDA and is ready to initiate a study with a leading Turkish pharmaceutical
company, Nobel Ilac Sanayii Ve Ticaret.